Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 5/20 | 0.41 |
| ▸ | CNR2 | P34972 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1897648 | 1.00 | PDE10A (0.47) | PDE10AKMT2ACNR1CNR2NPC1 | |
| SCHEMBL1894976 | 0.88 | PDE10A (0.48) | PDE10AKMT2ACNR1CNR2NPC1 | |
| SCHEMBL12668529 | 0.88 | PDE10A (0.52) | PDE10AKMT2ACNR1CNR2NPC1 | |
| SCHEMBL12668700 | 0.88 | PDE10A (0.48) | PDE10AKMT2ACNR1CNR2NPC1 | |
| SCHEMBL1894979 | 0.88 | PDE10A (0.48) | PDE10AKMT2ACNR1CNR2NPC1 | |
| SCHEMBL12674845 | 0.83 | PDE10A (0.45) | PDE10AKMT2ACNR1CNR2NPC1 | |
| SCHEMBL12675157 | 0.83 | PDE10A (0.45) | PDE10AKMT2ACNR1CNR2NPC1 | |
| SCHEMBL12675159 | 0.83 | PDE10A (0.45) | PDE10AKMT2ACNR1CNR2NPC1 | |
| SCHEMBL12674853 | 0.83 | PDE10A (0.45) | PDE10AKMT2ACNR1CNR2NPC1 | |
| SCHEMBL12675553 | 0.81 | P2RX7 (0.47) | PDE10AKMT2ACNR1CNR2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937643-B1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | SECOND GENOME INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8779144-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | EVOTEC (US) INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20110118287-A1 | Bicycloheteroaryl Compounds As P2X7 Modulators and Uses Thereof | RENOVIS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| EP-1937643-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | Renovis, Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007109160-A9 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS INC (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007109160-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118287-A1 | Bicycloheteroaryl Compounds As P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX1 | PDE10A 965/4885KMT2A 4684/4885CNR1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.